Jens Lagerstedt

List of Publications by Year
in descending order

46 papers	1,115 citations	430843 18 h-index	414395 32 g-index
47 all docs	47 docs citations	47 times ranked	1528 citing authors

#	Article	IF	Citations
1	Regulation of phosphate acquisition in Saccharomyces cerevisiae. Current Genetics, 2003, 43, 225-244.	1.7	135
2	Loss of ZnT8 function protects against diabetes by enhanced insulin secretion. Nature Genetics, 2019, 51, 1596-1606.	21.4	96
3	Identification, Expression, and Functional Analyses of a Thylakoid ATP/ADP Carrier from Arabidopsis. Journal of Biological Chemistry, 2007, 282, 8848-8859.	3.4	72
4	Electron Paramagnetic Resonance Spectroscopy of Site-directed Spin Labels Reveals the Structural Heterogeneity in the N-terminal Domain of ApoA-I in Solution. Journal of Biological Chemistry, 2007, 282, 9143-9149.	3.4	59
5	Single injections of apoA-I acutely improve in vivo glucose tolerance in insulin-resistant mice. Diabetologia, 2014, 57, 797-800.	6.3	53
6	Discoidal HDL and apoA-I-derived peptides improve glucose uptake in skeletal muscle. Journal of Lipid Research, 2013, 54, 1275-1282.	4.2	50
7	Mapping the Structural Transition in an Amyloidogenic Apolipoprotein A-I. Biochemistry, 2007, 46, 9693-9699.	2.5	45
8	Structural Modeling and Electron Paramagnetic Resonance Spectroscopy of the Human Na+/H+ Exchanger Isoform 1, NHE1. Journal of Biological Chemistry, 2011, 286, 634-648.	3.4	42
9	The fibrillogenic L178H variant of apolipoprotein A-I forms helical fibrils. Journal of Lipid Research, 2012, 53, 390-398.	4.2	41
10	Structural modeling of dual-affinity purified Pho84 phosphate transporter. FEBS Letters, 2004, 578, 262-268.	2.8	33
11	The â€œbeta-claspâ€•model of apolipoprotein A-I â€" A lipid-free solution structure determined by electron paramagnetic resonance spectroscopy. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 448-455.	2.4	32
12	Dual Actions of Apolipoprotein A-I on Glucose-Stimulated Insulin Secretion and Insulin-Independent Peripheral Tissue Glucose Uptake Lead to Increased Heart and Skeletal Muscle Glucose Disposal. Diabetes, 2016, 65, 1838-1848.	0.6	32
13	Plasma stem cell factor levels are associated with risk of cardiovascular disease and death. Journal of Internal Medicine, 2017, 282, 508-521.	6.0	27
14	Mutagenic and functional analysis of the C-terminus ofSaccharomyces cerevisiaePho84 phosphate transporter. FEBS Letters, 2002, 526, 31-37.	2.8	26
15	Structure of Apolipoprotein A-I N Terminus on Nascent High Density Lipoproteins. Journal of Biological Chemistry, 2011, 286, 2966-2975.	3.4	26
16	ApoA-1 improves glucose tolerance by increasing glucose uptake into heart and skeletal muscle independently of AMPKÎ±2. Molecular Metabolism, 2020, 35, 100949.	6.5	25
17	Superantigen activates the gp130 receptor on adipocytes resulting in altered adipocyte metabolism. Metabolism: Clinical and Experimental, 2014, 63, 831-840.	3.4	23
18	ApoA-I Milano stimulates lipolysis in adipose cells independently of cAMP/PKA activation. Journal of Lipid Research, 2015, 56, 2248-2259.	4.2	23

#	Article	IF	Citations
19	Site-specific glycations of apolipoprotein A-I lead to differentiated functional effects on lipid-binding and on glucose metabolism. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2822-2834.	3.8	22
20	ApoAI-derived peptide increases glucose tolerance and prevents formation of atherosclerosis in mice. Diabetologia, 2019, 62, 1257-1267.	6.3	20
21	Apolipoprotein A-I primes beta cells to increase glucose stimulated insulin secretion. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165613.	3.8	20
22	Secondary Structure Changes in ApoA-I Milano (R173C) Are Not Accompanied by a Decrease in Protein Stability or Solubility. PLoS ONE, 2014, 9, e96150.	2.5	19
23	Effects of Methylphosphonate, a Phosphate Analogue, on the Expression and Degradation of the High-Affinity Phosphate Transporter Pho84, in Saccharomyces cerevisiae. Biochemistry, 2004, 43, 14444-14453.	2.5	17
24	Apolipoprotein A-I attenuates LL-37-induced endothelial cell cytotoxicity. Biochemical and Biophysical Research Communications, 2017, 493, 71-76.	2.1	17
25	The secondary structure of apolipoproteinÂ A â€‐I on 9.6â€‐nm reconstituted highâ€‐density lipoprotein determined by EPR spectroscopy. FEBS Journal, 2013, 280, 3416-3424.	4.7	16
26	Conformational and aggregation properties of the 1â€“93 fragment of apolipoprotein Aâ€‐I. Protein Science, 2014, 23, 1559-1571.	7.6	16
27	Structural determinants in ApoA-I amyloidogenic variants explain improved cholesterol metabolism despite low HDL levels. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 3038-3048.	3.8	14
28	Structural and Functional Analysis of the ApolipoproteinA-I A164S Variant. PLoS ONE, 2015, 10, e0143915.	2.5	13
29	Imaging apolipoprotein AI <i>in vivo</i>. NMR in Biomedicine, 2011, 24, 916-924.	2.8	12
30	Characterization of the biochemical and biophysical properties of the Saccharomyces cerevisiae phosphate transporter Pho89. Biochemical and Biophysical Research Communications, 2013, 436, 551-556.	2.1	12
31	Structure and Function of the GTP Binding Protein Gtr1 and Its Role in Phosphate Transport in Saccharomyces cerevisiae. Biochemistry, 2005, 44, 511-517.	2.5	11
32	EPR assessment of protein sites for incorporation of Gd(III) MRI contrast labels. Contrast Media and Molecular Imaging, 2013, 8, 252-264.	0.8	11
33	Synchrotron radiation circular dichroism spectroscopy reveals structural divergences in HDL-bound apoA-I variants. Scientific Reports, 2017, 7, 13540.	3.3	11
34	Highâ€‐efficient bacterial production of human ApoAâ€‐I amyloidogenic variants. Protein Science, 2018, 27, 2101-2109.	7.6	7
35	Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability to mediate cholesterol efflux. Journal of Lipid Research, 2021, 62, 100004.	4.2	7
36	Properties of the Cysteine-less Pho84 Phosphate Transporter of Saccharomyces cerevisiae. Biochemical and Biophysical Research Communications, 2001, 287, 837-842.	2.1	5

#	Article	IF	Citations
37	Novel ABCA1 peptide agonists with antidiabetic action. Molecular and Cellular Endocrinology, 2019, 480, 1-11.	3.2	5
38	Molecular crowding impacts the structure of apolipoprotein Aâ€I with potential implications on in vivo metabolism and function. Biopolymers, 2016, 105, 683-692.	2.4	4
39	Antiâ€ApoAâ€I IgG antibodies are not associated with carotid artery disease progression and firstâ€time cardiovascular events in middleâ€aged individuals. Journal of Internal Medicine, 2019, 285, 49-58.	6.0	4
40	The Lipid Droplet: a Dynamic Organelle, not only Involved in the Storage and Turnover of Lipids. , 2009, , 1-26.		4
41	Secretory granule exocytosis and its amplification by cAMP in pancreatic Î²-cells. Diabetology International, 2022, 13, 471-479.	1.4	4
42	Structures of apolipoprotein A-I in high density lipoprotein generated by electron microscopy and biased simulations. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2726-2738.	2.4	2
43	A short peptide of the C-terminal class Y helices of apolipoprotein A-I has preserved functions in cholesterol efflux and in vivo metabolic control. Scientific Reports, 2020, 10, 18070.	3.3	2
44	Characterization of heterologues produced Gtr1 G-binding protein from Saccharomyces cerevisiae. Biochemical Society Transactions, 2000, 28, A199-A199.	3.4	0
45	Characterization of heterologues produced Gtr1 G-binding protein from <i>Saccharomyces cerevisiae</i>. Biochemical Society Transactions, 2000, 28, A392-A392.	3.4	0
46	Structural properties of functional HDL and variants of apoAâ€I. FASEB Journal, 2012, 26, 997.5.	0.5	0